Hancock Jaffe Laboratories, Inc.
File an IDE application with the FDA for the VenoValve U.S. pivotal trial
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 12 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- 5 Mar 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“expects to file its application with the FDA in the first quarter of 2021 seeking IDE approval for commencing the VenoValve U.S. pivotal trial.”
What we found
Evidence strength A What the grades mean
The company successfully filed its IDE application with the FDA for the VenoValve U.S. pivotal trial on March 5, 2021, which is within the first quarter of 2021.
-
A Hancock Jaffe Laboratories, Inc. 10-K filed 2021-03-31
“On March 5, 2021 we filed an IDE application with the FDA for the VenoValve U.S. pivotal trial.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- File
- Deliverable
- IDE application for VenoValve U.S. pivotal trial
- Where
- U.S.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Hancock Jaffe Laboratories, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-NVNO-023761 · Corrections policy